BNTX - BioNTech SE - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BNTX is currently covered by 16 analysts with an average price target of $150.7. This is a potential upside of $39.7 (35.77%) from yesterday's end of day stock price of $111.

BioNTech SE's activity chart (see below) currently has 174 price targets and 189 ratings on display. The stock rating distribution of BNTX is 69.74% BUY, 23.68% HOLD and 6.58% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 53.72% with an average time for these price targets to be met of 54 days.

Highest price target for BNTX is $171.44, Lowest price target is $110, average price target is $131.96.

Most recent stock forecast was given by TAZEEN AHMAD from BAML on 05-Aug-2025. First documented stock forecast 04-Nov-2019.

Currently out of the existing stock ratings of BNTX, 53 are a BUY (69.74%), 18 are a HOLD (23.68%), 5 are a SELL (6.58%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$134

$22.65 (20.34%)

$126

7 days ago
(05-Aug-2025)

7/14 (50%)

$22.93 (20.64%)

49

Buy

$133

$21.65 (19.44%)

$132

1 months 2 days ago
(10-Jul-2025)

2/6 (33.33%)

$19.08 (16.75%)

25

Buy

$138

$26.65 (23.93%)

$138

1 months 18 days ago
(25-Jun-2025)

14/35 (40%)

$33.2 (31.68%)

69

Hold

$110

$-1.35 (-1.21%)

$137

2 months 14 days ago
(29-May-2025)

5/9 (55.56%)

$9.75 (9.73%)

77

Hold

$116

$4.65 (4.18%)

$122

2 months 21 days ago
(22-May-2025)

10/11 (90.91%)

$16.93 (17.09%)

40

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BNTX (BioNTech SE) average time for price targets to be met?

On average it took 54 days on average for the stock forecasts to be realized with a an average price target met ratio 53.72

Which analyst has the current highest performing score on BNTX (BioNTech SE) with a proven track record?

SHANSHAN XU

Which analyst has the most public recommendations on BNTX (BioNTech SE)?

Shanshan Xu has 5 price targets and 3 ratings on BNTX

Which analyst is the currently most bullish on BNTX (BioNTech SE)?

Olga Smolentseva with highest potential upside - $342.36

Which analyst is the currently most reserved on BNTX (BioNTech SE)?

Chris Shibutani with lowest potential downside - -$1.35

BioNTech SE in the News

BioNTech SE (NASDAQ:BNTX) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

It’s been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative result overall – revenue fell 6.0% short of analyst estimates at €261m, and statutory losses were in line with analyst expectations, at €1.60...

GSK to Receive $370 Million From CureVac, BioNTech Patent Dispute Settlement

GSK (GSK) said Friday that it will receive $370 million from the mRNA patent settlement deal between PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?